Journal of Paediatrics and Child HealthVolume 58, Issue 5 p. 935-935 Heads UpFree Access SHINE trial of shorter course tuberculosis treatment First published: 02 April 2022 https://doi.org/10.1111/jpc.15957 edited by Craig Mellis (craig.mellis@sydney.edu.au) [Correction added on 12 April 2022, after first online publication: Figure 1 has been removed from the article.] AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat The World Health Organization (WHO) estimates that 1.1 million children worldwide became ill with tuberculosis (TB) in 2020. Treatment adherence is a possible issue in the development of multidrug-resistant TB. The SHINE trial randomised 1204 African and Indian children (median age 3.5 years, range 2 months to 15 years) diagnosed with respiratory sample smear-negative, ‘non-severe’ TB to either 4 or 6 months of anti-tuberculous treatment using child-friendly fixed dose combinations (8 weeks of isoniazid, rifampicin and pyrazinamide ± ethambutol followed by 8 or 16 weeks of isoniazid and rifampicin).1 Of these, 52% were male, 11% had human immunodeficiency virus (HIV) infection, and 14% had bacteriologically confirmed TB. Retention (95% at 72 weeks) and treatment adherence (94%) were very high. The primary endpoint, unfavourable outcome (treatment failure or death), occurred in 16 participants (3%) in the 4-month group compared with 18 (3%) in the 6-month group (adjusted difference, −0.4%; 95% CI, −2.2 to 1.5). Adverse events mainly occurred in the first 8 weeks of treatment and were equally common (8%) in both groups. As a result of the SHINE trial, new WHO guidelines recommend that children with non-severe TB can now receive 4 months of anti-TB treatment. The challenges are accurate classification of ‘non-severe’ disease in resource-limited settings where disease burdens are highest, and whether clinicians in developed countries will feel comfortable treating for 4 months before more clinical experience accumulates. Reference 1Turkova A, Wills GH, Wobudeya E et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N. Engl J Med 2022; 399: 911– 22. CrossrefWeb of Science®Google Scholar Reviewers: David Isaacs (david.isaacs@health.nsw.gov.au) and Ben Marais (ben.marais@health.nsw.gov.au), Children's Hospital at Westmead and University of Sydney Volume58, Issue5May 2022Pages 935-935 ReferencesRelatedInformation
Read full abstract